Drug Pricing
Our work in Drug Pricing
-
Finding an Answer to the Hepatitis C Cost Conundrum
We need to shift our treatment strategy to one that treats patients at the optimal time, thereby maximizing the treatment’s effectiveness and controlling costs for payers.
Categorized in -
What the Candidates Don’t Get About Drug Prices
What should the candidates really be talking about when it comes to drug prices?
Categorized in -
What the Candidates Don’t Get About Drug Prices
Currently, Medicare lets private payers negotiate for drug discounts, and Medicare just pays its part of the cost.
Categorized in -
A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand
This study estimated the cost of aPCC and rFVIIa prophylaxis relative to rFVIIa on-demand treatment cost based on rFVIIa doses reported in US registries, and found that aPCC prophylaxis may be cost saving for managing hemophilia patients with inhibitors who bleed frequently and infuse significant quantities of rFVIIa on demand.
Categorized in -
Comparative Effectiveness of Panitumumab (P) and Cetuximab (C) in Metastatic Colorectal Cancer (mCRC) with Wild-Type KRAS (WTKRAS)
This study evaluated the comparative effectiveness from a societal perspective of panitumumab and cetuximab in metastatic colorectal cancer with wild-type KRAS, and found that panitumumab has a cost advantage over cetuximab.
Categorized in -
Comparative Effectiveness of FOLFIRINOX (FOL) versus Gemcitabine and Nab-Paclitaxel (GNP) for the First-Line Treatment of Metastatic Pancreatic Cancer
This study compared the effectiveness and costs of combination chemotherapy with FOL and GNP in metastatic pancreatic cancer, including the costs of toxicities and supportive medications from a societal perspective, and found that FOL showed a slightly higher cost but higher life expectancy per quality-adjusted life-year as a first-line treatment.
Categorized in -
Five Laboratory Tests Predict Patient Risk and Treatment Response in Hepatitis C: Veterans Affairs Data from 1999-2010
This study identified five laboratory tests to predict increasing risk of liver-related events for patients with hepatitis C virus and documents that delaying treatment until after an abnormal lab test diminishes effectiveness of treatment with interferon alpha plus ribavirin.
Categorized in -
The Economic Promise of Delayed Aging
Expanded biomedical research to delay aging appears to be a highly efficient way to forestall disease and extend a healthy life.
Categorized in -
A System to Build Distributed Multivariate Models and Manage Disparate Data Sharing Policies: Implementation in the Scalable National Network for Effectiveness Research
The authors implemented distributed multivariate models for federated networks in which patient-level data is kept at each site and data exchange policies are managed in a study-centric manner to implement massively parallel computation methods and a new policy management system to enable each study initiated by network participants to define the ways in which data may be processed, managed, queried, and shared.
Categorized in -
Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in US and Canadian Clinical Practice
This study revealed substantial variation in subcutaneous immunotherapy regimens (SCIT) and showed that SCIT requires patient commitment to a long-term treatment regimen involving numerous clinic visits and resources for administration.
Categorized in